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 ABSTRACT 
 
OBJECTIVE:  The objective of this selective EBM review is to determine whether or not use of 
electroanalgesic therapy decreases neuropathic pain symptoms in diabetic patients  
STUDY DESIGN: Review of a 2 randomized control trial published in 2013 and 2011 published in the 
English language and an observational study published in 2010 in the German language translated into 
English.  
DATA SOURCES: One randomized, double-blind control trial comparing frequency-modulated 
electromagnetic stimulation vs placebo in reduction of diabetic neuropathic pain, one randomized, control 
trial comparing microcurrent transcutaneous electric nerve stimulation vs placebo in reduction of painful 
diabetic neuropathy and a observational study using baseline comparison of the observed group at the 
beginning of the treatment vs the end of the treatment. 
OUTCOMES MEASURED:  Pain is measured  through various scales administered in their respective 
studies. The Visual Analogue Scale was used to measure day and night pain, the Neuropathic Pain Score 
administered to assess pain intensity and the Thermal Sensory Analyzer to assess cold, warmth, cold pain 
and heat pain.  
RESULTS: Bosi et al. demonstrated significant reduction in day and night pain in treatment group vs 
placebo group. Gossrau et al. did not conclude that applied transcutaneous electrotherapy showed superior 
reduction of pain compared to placebo group. Moharic and Burger concluded there were no statistically 
significant changes or thermal pain perception thresholds after transcutaneous electrotherapy. 
CONCLUSIONS: Although some pain relief was reported by participants in these studies, 
collectively, all three studies have were unable to exhibit significant evidence of lasting DPN 
pain relief using electroanalgesic treatment.  
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INTRODUCTION 
Peripheral neuropathy is a common complication in diabetes type 1 and type 2 patients 
that often manifests as pain, paresthesia, and numbness in their upper and lower extremities.
1,2
 
The pathology of diabetic peripheral neuropathy (DPN) is complex and primarily involves 
atherosclerosis of the endoneural vascular supply leading to nerve ischemia and axonal 
atrophy.
2,3
  Diabetic peripheral neuropathy (DPN) typically presents as a loss of sensation 
beginning in the toes and progresses proximally. Patients often describe chronic neuropathic pain 
as burning, pins and needle tingling, and diffuse aching.
1
 Hyperalgesia, allodynia and loss of 
balance and coordination are also complaints associated with DPN.
6
  Manifestations of 
symptoms range from mild to severe and in some cases physical debilitation.
6
   
25.8 million people in the United States have diabetes and 79 million people are 
prediabetic. It is estimated that 60-70% of diabetes patients suffer some form of neuropathy. 27% 
of direct medical cost of diabetes is attributed to diabetic peripheral neuropathy totaling a cost of 
$10.9 billion dollars spent annually on treatment.
5
  Although the mechanism of the disease is 
poorly understood, it is widely thought that hyperglycemia causing changes in the blood vessels 
supplying the peripheral nerves underlie the mechanisms involved in microvascular damage and 
hypoxia.
7 
 
Management of painful DPN poses a large challenge to the medical community.
3
  Current 
treatment only reduce associated symptoms by 30-50% and due to lack of sufficient knowledge 
concerning the pathogenesis of the disease there are no curative treatments that can fully provide 
complete relief of symptoms.
7 
There are five main classes of medications used for the 
management of peripheral neuropathic pain: tricyclic antidepressants, anticonvulsants, serotonin-
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norepinephrine reuptake inhibitors, opiates and topical analgesics.
7
 Medications are the mainstay 
of DPN treatment but they are unsuccessful in providing larger numbers of relief 
notwithstanding the long list of adverse effects and complex drug interactions for patients on 
medications for comorbid conditions.
7 
Based on the gate control theory electroanalgesic therapy is being explored in providing a 
physiological block and activating an pain inhibitory system as a means to address the 
neuropathic pain in diabetic patients. 
OBJECTIVE 
The objective of this systematic review is to determine whether or not electroanalgesic 
therapy decreased neuropathic pain in diabetic patients. 
 
METHODS 
 The populations chosen were diabetic patients > 18 years old who suffer from peripheral 
neuropathic pain with the studies further selecting subjects with symptomatic DPN affecting the 
lower extremities that have suffered symptoms more than a year. The intervention in all studies 
were electroanalgesic therapy via micro-transcutaneous electrical nerve stimulation (TENS) units 
or frequency modulated neural stimulation (FREMS) units.
1
   
 Key words used in the searches were “diabetic neuropathies”, “transcutaneous nerve 
stimulation”, and “electroanalgesia”.  All articles were published in peer-reviewed journals and 
in the English language with one article translated into English from the German language.  The 
author searched the articles through PubMed and selected articles based on the relevance to the 
clinical question, human subjects and the outcomes that included patient-oriented evidence that 
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matters.  Inclusion criteria consisted of studies where design was either observational or 
randomized, single blinded or double blinded, placebo controlled, studies that included diagnosis 
of diabetes mellitus type 1 or type 2 for at least 1 year, patients who experience symptomatology 
of painful diabetic neuropathy, and patients > 18 years of age. In  the study conducted by Bosi et 
al, further selection of participants included patients with a HbA1c <11.0%,  abnormalities in 
amplitude, latency or conduction velocity in at least one motor nerve, and a Michigan Diabetes 
Neuropathy Score (MDNS) equal or greater than 7 points.
1  
Exclusion criteria in this study 
consisted of patients with previous treatment with TENS or other electrotherapy for DPN, 
implantable pacemaker, defibrillator or neurostimulator, presence of active foot ulcer and/or 
previous major amputation of lower extremities and any concomitant sever disease limiting 
compliance to study procedures or life expectancy.  The criteria for patients selected in the 
Gossrau et al study included a HbA1c <8.0%, gammaglutamyltransferase (GGT) <1.4 µmol/L, 
normal creatinine and blood cell counts; and current pain intensity of at least 4/10 on a numerical 
rating scale (NRS).
2 
 The exclusion criteria in this study consisted of patients with implanted 
pacemakers, heart defibrillators, brain stimulators, history of alcohol abuse and malignancies.
2 
Selection of patients in the Moharic and Burger study was made at an outpatient clinic for 
diabetic foot with diabetes mellitus type 2, further selecting patients who agreed to at least two 
items of the Michigan Neuropathy Screening Instrument (MNSI).
3 
The exclusion criteria in the 
Moharic and Burger study included patients with other non-diabetic neuropathies, significant 
pain of other etiologies or peripheral vascular disease.  
 In the study conducted by Bosi et al treatment was administered via the Aptiva device.
1
 
Four pairs of electrodes were applied to both lower extremities and biphasic sequences of 
asymmetric and electrically balanced pulses with an active phase of high negative voltage spike 
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(-300V) and short duration 10-100 microseconds proceeded by a recharging phase of low voltage 
and long duration (.9-999ms) with variable pulse frequency 1-1000Hz were applied to treatment 
groups.
1 
Electrodes were also applied to the placebo group but no electrical impulses were 
administered.  FREMS or placebo treatments were 30 minutes in length and completed sessions 
consisted of 10 consecutive treatments administered at least 24 hours a part within a 21 day time 
frame.
1
 Studies by Gossrau et al. were conducted over a 4 week period consisting of 3 visits per 
week.  The treatment group were administered 30 minutes of low-frequency microcurrent (30-40 
microA) via skin electrodes placed on the proximal dorsum pedis and on top of caput fibulae on 
both legs. In the placebo group the electrodes were not connected to the TENS unit-microcurrent 
and did not induce sensations or muscle twitching.
2
 
 
Duration of the study consisted of 3 visits 
over a 4 week period.  In the last study reviewed by Moharic and Burger titled, transcutaneous 
electrotherapy was administered to patients by portable unit generating current with a pulse 
width of 30-260ms, intensity 0-14mA and frequency 2-150 mHz in constant, burst or modulated 
form.  5 x 5cm self-adhesive PALS electrodes placed proximally 10 cm above internal or 
external malleolus and distally in the sole or dorsum of the foot, alternating the two 
configurations each day on both lower extremities x 3 consecutive hours daily for 3 weeks.
3 
OUTCOMES MEASURED 
 Outcomes measured in these studies were all based on the reduction of pain scale rating 
reported by patients.  Other outcomes measured were cold, warm, cold pain and heat pain 
thresholds, vibration perception thresholds and touch perception thresholds, pain intensity, pain 
interference with activity of daily life and depression and tactile sensations.  Indices utilized to 
measure outcomes were: Thermal Sensory Analyser, Vibratory Sensory Analyser, Von Frey’s 
hair, Pain Disability Index, Neuropathic Pain Score, Center for Epidemiologic Studies  
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Table 1: Demographics and characteristics of included studies 
Study Type #Pts Age 
years 
Inclusion Criteria Exclusion Criteria W
D 
Interventions 
Gossrau
1 
RCT 41 67+ 12  diagnosis of  type 1 or 
type 2 diabetes mellitus 
for at least 1 year and 
have painful diabetic 
neuropathy (PND), 
diagnosed by an 
experienced neurologist 
or diabetologist, HbA1c 
<8%, GGT < 1.4µmols/L, 
normal results for 
creatinine and blood cell 
counts; and current pain 
intensity of at least 4/10 
on a numerical rating 
scale (NRS) 
 
implanted 
pacemaker, heart 
defibrillator, brain 
stimulator, history of 
alcohol abuse and 
malignancy 
 
0 4 weeks, 3 visits/week, 
tx group: 30 mins of 
low-frequency 
microcurrent 30-40 
microA via skin 
electrodes places on 
proximal dorsum pedis 
and on top of caput 
fibulae on both legs 
Placebo group: 
Identical to treatment 
group but electrodes 
not connected to 
micro-TENS unit 
 
Bossi
2 
RCT 164 18-75  Patients with documented 
type 1 or type 2 diabetes 
>1 year and HbA1C , 
11%, DPN affecting LEs 
with at least one positive 
sensory symptom, 
abnormalities in 
amplitude (<6mV), 
latency (>6.5ms) or 
conduction velocity 
(<40m/s) in at least one 
motor nerve (tibial or 
deep peroneal) and/or in 
sural nerve, measurable 
sensitive NCV and 
evocable potential in the 
sural nerve, a MDN Score 
>7 points, stable dose of 
pain medications or other 
diabetic neuropathy 
medications during month 
leading up to enrollment 
Previous tx with 
TENS or other 
electrotherapy, 
implanted 
pacemaker, 
defibrillator or 
neurostimulator, 
presence of active 
foot ulcer, 
amputation of LEs, 
concomitant severe 
disease limiting 
compliance to study 
procedures or life 
expectancy 
54 Treatment with 
FREMS (biphasic 
sequences, asymmetric 
and electrically 
balanced pulses with 
an active phase of -
300V and short 
duration proceeded by 
a recharging phase of 
low voltage and long 
duration; variable 
pulse frequency 1-
1000Hz.) 
Placebo – no electrical 
pulses 
FREMS and Placebo 
administered via 
Aptiva device: 4 pairs 
of electrodes applied 
to LEs 
 
Moharic
3 
RCT 46 43-75 Diabetes mellitus type 2, 
stable glycemic control, 
chronic PDN (at least 6 
months) in LEs, at least 
two items of the MNSI, 
one relevant to general 
asthenia and one relevant 
to perivascular disease.  
patients with other 
non-diabetic 
neuropathy, 
significant pain of 
other etiology or 
peripheral vascular 
disease 
0 Portable TENS unit, 
pulse width of 30-
260ms, intensity 0-
14mA and frequency 
2-150 mHz in 
constant, burst or 
modulated form.  
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Depression Scale, Visual Analogue Scale, Semmes-Weinstein monofilament test. For the 
purpose of comparison of studies in this review, focus is geared towards indices measuring pain. 
RESULTS 
The Bosi et al study was a double-blind, placebo controlled RTC. Assignment of patients 
to treatment were randomized and the randomization allocation were concealed from those 
enrolling the subjects into the study.
1
  110 patients were found eligible for the study and 54 were 
randomly assigned to receive FREMS and 56 received placebo.
1
 Assessments of participants 
were collected 8 times over a 51 week period. All patients were analyzed in the groups they were 
originally randomized into.
1
 At the conclusion of the study, 32% of subjects were lost and a 
“worst-case” analysis was not completes on subjects lost.1 The study showed that both the VAS 
score for nighttime pain and daytime pain were significantly reduced in the intention-to-treat 
population compared to the placebo group.
1
 Reduction of >30% or >50% scoring was 
significantly higher in the FREMS treatment group in comparison to the placebo group after the 
second and third treatment sessions.
1
 Data in the study was continuous showing an average 
change in VAS scoring between treatment and placebo groups and authors reported outcomes 
through a change in mean from baseline (baseline values shared in table 2).
1
 The precision of the 
estimate of the treatment effect was P=0.02 which demonstrates statistical significance.
1
 This 
trial confirms safety and efficacy of FREMS in reducing pain in diabetic patients with PDN. 
1 
Table 2: Baseline characteristic of study participants (values as mean with standard deviation)
1 
Baseline Characteristics Placebo (n=51) FREMS (n=50) 
Night-time pain, VAS score 45.2+29.6 41.3+29.7 
Day-time pain, VAS score 40.9+24.0 31.6+26.3 
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 The Gossrau et al study included 41 patients, 22 in the treatment group and 19 in the 
placebo group.
2
 Characteristics such as body mass index, duration of diabetes and PDN 
symptoms and HbA1c of patients were equally distributed through the treatment and placebo 
group.
2
  Randomization allocation was concealed and intention to treat analysis was applied to 
the summation of scoring submitted by patients. Scores from the Neuropathic Pain Scale (NPS) 
and Pain Disability Index (PDI) were compared before treatment, after treatment and a month 
following completion of the treatment.
2
 There was no significant difference between the 
treatment and placebo group after the first two measurements(P>0.18).
2
 There was also no 
significance found in the comparison of the NPS score at the beginning of treatment and after the 
follow-up visit a month after treatments ended (P>0.5).
2
  None of the treatment effects showed 
evidence of precision because they all exceeded p-value.
2
  The relative risk ratio (RRR) was 
calculated to be -0.48, the absolute risk ratio (ARR) -0.253, and the numbers needed to treat 
(NNT) -4 show a small treatment effect.
2 
 For the PDI score, table 3 displays that the items of the 
PDI were not influenced by the micro-TENS treatments. 
Table 3: PDI score not influenced by micro-TENS (values as mean with standard deviation)
2 
 Treatment 
Group before 
treatment – 
T1 
Placebo 
Group before 
treatment – 
T1 
Treatment 
Group after 4 
weeks 
treatment 
Placebo 
Group after 4 
weeks 
treatment 
Treatment 
group after 1 
month  
follow-up 
Placebo 
group after 1 
month 
follow-up 
P value 
difference 
T1/T2 
P value 
difference 
T1/T3 
 
 
PDI 
 
 
 
 
22.05+ 16.5 
 
 
21.79+ 15 
 
 
17.7+ 15.5 
 
 
  18+ 14.6 
 
 
19.45+ 15.6 
 
 
18.05+13.5 
 
 
    P > 0.8 
 
 
P > 0.5 
 
 The Moharic and Burger study was an observation study with 46 participants.
3
 Outcomes 
assessed were cold pain and heat pain thresholds and comparisons of outcomes at the beginning 
of treatment and 1 month after completion were assessed reporting change in mean from 
baseline.
3
 Cold and heat pain were measured at four sites: the thenar eminence, dorsum of the 
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foot, 5cm below the fibular head and the anterior part of the thigh.
3
 Change in thenar cold and 
heat pain were the only two significantly changed thresholds with p-value of 0.0001 as seen in 
table 4.
3 
Table 4: Results from statistical tests of sensory thresholds (thermal thresholds in ºC)
3 
 Threshold Baseline Median After treatment 
Median 
One Month after 
treatment Median 
P value  
Thenar  Cold pain 
Hot pain 
4.1 
47.4 
13.2 
45.0 
15.9 
44.5 
0.0001* 
0.0001* 
Dorsum of foot Cold pain 
Hot pain 
0.0 
50.0 
0.0 
50.0 
3.5 
50.0 
0.2044 
0.7922 
Lateral part of 
leg 
Cold pain 
Hot pain 
2.7 
50.0 
1.6 
49.5 
9.9 
48.6 
0.1202 
0.1566 
Anterior part 
of thigh 
Cold pain 
Hot pain 
2.2 
47.7 
8.1 
47.9 
12.1 
47.4 
0.1306 
0.3944 
 
DISCUSSION 
All three studies were unable to exhibit evidence of lasting DPN pain relief using 
electroanalgesic treatment.  In the Bosi et al study, there was a notable reduction in the VAS 
scoring at the conclusion of the study however, the pain reduction was not sustained as many 
patients returned to baseline scoring discovered during a 3 month follow up survey.
1 
 In the 
Gossrau et al study, the lack of significance found after NPS comparisons between treatment and 
placebo group exhibited no difference in reduction pain intensity, pain tolerance and presence of 
burning or stabbing pain quality after treatment with the TENS unit.  The lack of significant 
differences in outcomes showed that general reduction of pain when applying TENS is not a 
superior treatment to the placebo treatment.
2 
 Moharic and Burger also concludes the that TENS 
did not display significant findings regarding baseline pain thresholds compared to post 
treatment thresholds.
3  
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Each study had a limitation in design and implementation of investigation. The Bosi et al. 
study had a limitation on their inclusion criteria selecting patients who demonstrated mild 
symptomatology excluding diabetic patients with more severe symptoms therefore, possibly 
excluding the findings of the study’s application to this population.1  In the Gossrau et al study, 
the lower intensity of the currents in a micro-TENS units versus a conventional TENS unit could 
be attributed to the low therapeutic efficacy of the treatment.
2 
CONCLUSION 
Two RCTs and one observational study were systematically reviewed for the 
effectiveness of electroanalgesic therapy decreasing neuropathic pain in diabetic patients. 
Collectively, these studies do not support the efficacy of this modality in the treatment of 
diabetic peripheral neuropathic pain. However, the Gossrau et al and Mohari and Burger studies 
found lack of significance in comparison groups limitations in the inclusion criteria as well as the 
inconsistencies in the modalities of electroanalgesic therapies used across all three studies, there 
does remain the question if the ineffectiveness of this treatment is deemed as a conclusive 
finding.  The safety of electroanalgesic therapy has been demonstrated in all three studies but 
evidence of the efficacy of these treatments is lacking. Generally, any evidence of treatment for 
diabetic peripheral neuropathic pain is quite limited. There are currently a relatively small 
number of studies published on this mode of DPN treatment.  
Future study is warranted to evaluate electroanalgesic therapy in a more consistent and 
comprehensive evaluation in modality and in the breadth of patient population.  In terms of 
safety, efficacy and cost it would be of great benefit for future studies to address comparisons of 
therapies such as cost-effectiveness studies of the different treatments as to provide more 
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information to prescribing physicians and to diabetes patients while exploring the best options 
for treatment.  
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